Jasper Therapeutics appointed Vishal Kapoor as a Class I director and announced amendments to their bylaws; they also issued a press release regarding positive Phase 1 data for briquilimab in combination with fludarabine and low-dose irradiation in older adults with AML or MDS undergoing transplant.